Su Ruifang

Professor at Peking Union Medical College Hospital, lead investigator of the China Phase I/III trial

Appears in 1 story

Stories

iRegene photoreceptor cell therapy for retinitis pigmentosa cleared for trials in US and China

Leading the Phase I/III trial of NouvSight001 in China

About 1.5 million people worldwide have retinitis pigmentosa, an inherited disease that destroys the retina's light-sensing cells and can end in blindness. The only approved treatment covers patients with a specific RPE65 gene mutation — a small fraction of the affected population.

Updated 1 hour ago